<DOC>
	<DOCNO>NCT01503944</DOCNO>
	<brief_summary>The purpose study evaluate ability identify individual dopaminergic degeneration group patient clinical diagnosis either dementia Lewy body ( DLB ) idiopathic Parkinson 's disease differentiate Alzheimer 's disease ( AD ) control subject .</brief_summary>
	<brief_title>A Trial 18F-AV-133 18F-AV-45 Positron Emission Tomography ( PET )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Inclusion Criteria DLB : Male female &gt; 50 year age Meet diagnostic criterion probable DLB establish DLB Consortium ( McKeith et al. , 2005 ) Inclusion Criteria AD : Male female &gt; 50 year age Meet NINCDS criterion probable AD Mini Mental State Examination ( MMSE ) score screen 10 24 inclusive Inclusion Criteria PD : Male female &gt; 50 year age Have probable PD accord follow criterion ( Gelb et al. , 1999 ) : Presence 2 follow 3 feature : rest tremor , rigidity , bradykinesia ; Documented history sustain ( &gt; 6 month ) improvement Levodopa ( LDOPA ) dopamine agonist Absence atypical clinical feature possible sign symptom suggest another cause parkinsonism history frequent fall prominent early feature , localize brain lesion ( ) neuroleptic use Asymmetric onset A diagnosis PD make within 4 year prior enrollment Normal subject : Are male female &gt; 50 year age Have MMSE score &gt; 29 , cognitively normal psychometric test battery screen Have sign symptom clinically meaningful parkinsonism Have history current diagnosis neurologic disease Have evidence clinically significant cerebrovascular disease Have evidence MRI biomarker study suggest presence CNS pathology associate study disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>